Birch
pollen allergy is among the most prevalent
pollen allergies in Northern and Central Europe. This
IgE-mediated disease can be treated with allergen immunotherapy (AIT), which typically gives rise to
IgG antibodies inducing tolerance. Although the main mechanisms of allergen immunotherapy (AIT) are known, questions regarding possible Fc-mediated effects of
IgG antibodies remain unanswered. This can mainly be attributed to the unavailability of appropriate tools, i.e., well-characterised recombinant
antibodies (rAbs). We hereby aimed at providing human rAbs of several classes for mechanistic studies and as possible candidates for passive immunotherapy. We engineered
IgE,
IgG1, and
IgG4 sharing the same variable region against the major birch pollen
allergen Bet v 1 using Polymerase Incomplete Primer Extension (PIPE) cloning. We tested
IgE functionality and
IgG blocking capabilities using appropriate model cell lines. In vitro studies showed
IgE engagement with FcεRI and CD23 and Bet v 1-dependent degranulation. Overall, we hereby present fully functional, human
IgE,
IgG1, and
IgG4 sharing the same variable region against Bet v 1 and showcase possible applications in first mechanistic studies. Furthermore, our
IgG antibodies might be useful candidates for passive immunotherapy of birch
pollen allergy.